Blue Owl Capital has agreed to acquire Sila Realty Trust in an all-cash deal valued at about $2.4 billion, expanding its push into healthcare real estate at a time when alternative asset managers are looking for steadier, income-producing assets.The acquisition will be made through Blue Owl’s real assets division and includes Sila’s portfolio of 137 real estate properties plus three undeveloped land parcels across 65 U.S. markets.
Under the terms of the agreement, Blue Owl will pay $30.38 per share for all outstanding Sila shares. That represents a 19% premium to Sila’s closing price of $25.53 on April 17, the trading day before the announcement. Investors responded quickly: Sila Realty shares jumped more than 19% in early trading, while Blue Owl’s stock was broadly unchanged and later moved only modestly higher, roughly in line with the broader U.S. financials index.
The deal is significant because it highlights where Blue Owl sees growth inside its broader investment platform. The firm’s real assets division accounts for about one quarter of Blue Owl’s roughly $307 billion in assets under management. That unit invests in sectors such as industrial facilities, data centers, and property-backed credit, and it added assets faster than Blue Owl’s other business lines last year. The real assets division grew by $17 billion in 2025, helped in part by a deal originally struck in 2024 to buy data center developer IPI.
Buying Sila gives Blue Owl a larger foothold in healthcare-related property, a segment that investors often view as relatively defensive because demand is tied to medical services rather than more cyclical parts of the economy. The portfolio’s size and spread across dozens of markets suggest Blue Owl is acquiring a national platform rather than a niche local portfolio. That likely gives the buyer more scale and diversification in a sector where rent stability and long-term occupancy can be attractive.
The transaction also comes at an interesting moment for Blue Owl itself. The company shares have fallen more than 30% so far this year and have dropped below the price where the firm first entered the public market in 2021. Investors have been uneasy about several pressures affecting large alternative asset managers, including fears that software businesses they invested in or lent to could be disrupted by artificial intelligence, as well as broader questions about growth prospects and lending standards following a few high-profile bankruptcies. Blue Owl had come under added scrutiny after a proposed merger last year involving a non-traded private credit vehicle and a traded one raised concerns that wealthy individuals could face losses.
Against that backdrop, the Sila deal may serve two purposes for Blue Owl. First, it expands the firm’s holdings in a tangible asset class that can generate regular income. Second, it may help reassure investors that Blue Owl is continuing to build out its real-assets platform in areas less exposed to some of the AI-related disruption worries affecting other parts of alternative finance.
Overall, the acquisition was a strategic expansion rather than a transformational reinvention. Blue Owl is using cash to buy a healthcare REIT with a large national footprint, deepen one of its fastest-growing business segments, and add more property exposure at a time when investors are pushing alternative asset managers to show resilience and discipline. Sila shareholders are getting a clear premium, and Blue Owl is betting that healthcare real estate will strengthen its long-term growth story.
